Nephros, Inc. (NEPH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Nephrologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 27/100 (MEDIUM), 32.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.53% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Nephros (NEPH) Q2 2026 Earnings Call Transcript
- Nephros Inc (NEPH) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge ...
- Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026
- Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET
- Nephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water
- Nephros Announces Financial Results for Quarter Ended March 31, 2026
- Nephros Schedules First Quarter 2026 Financial Results Conference Call
- Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Effects of a 16-week physical training on clinical outcomes in patients with hypertension and chronic kidney disease: NEPHROS post-trial follow-up. — Cad Saude Publica 2022 PMID 35584433
- The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. — Nephrol Dial Transplant 2001 Nov PMID 11682661
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Nephros, Inc..
Full NEPH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.